Development of a rapid screening instrument for mild cognitive impairment and undiagnosed dementia

N Kyle Steenland1, Courtney M Auman, Purvi M Patel

  • 1Department of Environmental and Occupational Health, School of Public Health, Emory University, Atlanta, GA 30322, USA. nsteenl@sph.emory.edu

Insights

A quick screening tool combining the Mini-Cog and Functional Activities Questionnaire (MC-FAQ) accurately identifies mild cognitive impairment (MCI) and dementia. This method aids in early detection of cognitive decline in older adults.

Area of Science:

  • Gerontology
  • Neurology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is a precursor to Alzheimer's disease (AD).
  • Early detection of cognitive impairment is crucial for timely intervention.
  • Existing screening methods may require significant time or resources.

Purpose of the Study:

  • To evaluate the efficacy of a combined Mini-Cog and Functional Activities Questionnaire (MC-FAQ) screening tool.
  • To determine if MC-FAQ can accurately identify individuals with MCI and undiagnosed dementia.
  • To assess the utility of MC-FAQ as a rapid screening instrument for cognitive impairment in the elderly.

Main Methods:

  • A cross-sectional study was conducted.
  • Participants underwent the Mini-Cog (clock drawing, 3-item recall) and the informant-based Functional Activities Questionnaire (FAQ).
  • A consensus diagnosis (Normal, MCI, Dementia) was established by expert clinicians, with a classification tree algorithm used for analysis.

Main Results:

  • The MC-FAQ predicted the consensus diagnosis with 83% accuracy and a weighted kappa of 0.81.
  • When dichotomized into Normal vs. Abnormal, MC-FAQ achieved 89% sensitivity, 90% specificity, and 95% positive predictive value.
  • The tool effectively discriminates between cognitively normal individuals, those with MCI, and those with dementia.

Conclusions:

  • The combined MC-FAQ is an accurate and efficient screening tool for identifying cognitive impairment, including MCI and dementia.
  • Its ease of administration makes it suitable for widespread use in elderly populations.
  • MC-FAQ can aid clinicians in the early detection of cognitive decline, potentially facilitating earlier management of conditions like Alzheimer's disease.